Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, with a primary focus on neuromuscular diseases.

Voir plus

October 16, 2020

Biophitys will participate in the following events:

  • Mid-Cap Event :October 19 & 20th
  • Galien Week of Innovation: Oct 26-30
October 13, 2020

First US Patient Enrolled in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release

September 30, 2020

Biophytis Trading will resume on September 30, 2020 at 3.00pm CEST. Read the Press Release

Our science

Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.

See more


Our lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.

See more



Biophytis has been listed on the market Euronext Growth Paris
since July 13, 2015.

ISIN : FR0012816825
Ticker: ALBPS
Type of listing : continuous
Number of outstanding shares: 75 038 936  (as of October 1st, 2020)
Eligible for PEA and PEA-PME equity saving plans

Click here for live stock price

See more